Zanubrutinib Plus Venetoclax Effective in Patients With CLL/SLL Regardless of Del(17p)/TP53 Mutation
Zanubrutinib plus venetoclax may be safe and effective regardless of 17p deletion (del[17p]) or TP53 mutational status.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)